Search Result

Results for "

IgG4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) ANGPTL (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (3) c-Fms (3) c-Met/HGFR (1) CCR (1) CD20 (1) CD22 (1) CD28 (1) CD3 (2) CD38 (1) CD47 (2) CGRP Receptor (1) Complement System (1) CTLA-4 (2) CXCR (1) EGFR (1) Factor Xa (1) GCGR (1) HIV (2) Integrin (3) Interleukin Related (13) LAG-3 (4) MMP (1) NF-κB (1) P-selectin (1) PCSK9 (1) PD-1/PD-L1 (23) RANKL/RANK (1) SARS-CoV (2) Tau Protein (3) TGF-beta/Smad (1) TGF-β Receptor (3) Tim3 (1) TNF Receptor (4) Toll-like Receptor (TLR) (1) VEGFR (1)
By Research Areas:	Cancer (54) Cardiovascular Disease (4) Infection (5) Inflammation/Immunology (54) Metabolic Disease (4) Neurological Disease (7)

By Targets:

ADC Antibody (3)

ANGPTL (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (3)

c-Fms (3)

c-Met/HGFR (1)

CCR (1)

CD20 (1)

CD22 (1)

CD28 (1)

CD3 (2)

CD38 (1)

CD47 (2)

CGRP Receptor (1)

Complement System (1)

CTLA-4 (2)

CXCR (1)

EGFR (1)

Factor Xa (1)

GCGR (1)

HIV (2)

Integrin (3)

Interleukin Related (13)

LAG-3 (4)

MMP (1)

NF-κB (1)

P-selectin (1)

PCSK9 (1)

PD-1/PD-L1 (23)

RANKL/RANK (1)

SARS-CoV (2)

Tau Protein (3)

TGF-beta/Smad (1)

TGF-β Receptor (3)

Tim3 (1)

TNF Receptor (4)

Toll-like Receptor (TLR) (1)

VEGFR (1)

By Research Areas:

Cancer (54)

Cardiovascular Disease (4)

Infection (5)

Inflammation/Immunology (54)

Metabolic Disease (4)

Neurological Disease (7)

Inhibitors & Agonists

Peptides

113

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Pembrolizumab 10+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Lemzoparlimab TJ011133; TJC4	CD47	Cancer
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .

Galcanezumab LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

Ieramilimab LAG525; IMP701	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .

Garadacimab 1 Publications Verification CSL312	Factor Xa	Cardiovascular Disease
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .

Garetosmab REGN 2477	TGF-β Receptor	Inflammation/Immunology
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .

Ibalizumab TMB-355; TNX-355	HIV	Infection
Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .

Tralokinumab	Interleukin Related	Inflammation/Immunology
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

Reflocibart	VEGFR	Inflammation/Immunology
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Pamvatamig	EGFR	Inflammation/Immunology
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Vilamakitug XB-2001	PD-1/PD-L1	Inflammation/Immunology
Vilamakitug is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Pradusinstobart LVGN-3616	PD-1/PD-L1	Inflammation/Immunology
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Negalstobart	LAG-3	Inflammation/Immunology
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Roconkibart	Interleukin Related	Inflammation/Immunology
Roconkibart is an anti-IL17A human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

Burfiralimab hzVSF-v13	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

Nezastomig REGN-5678	CD28	Inflammation/Immunology
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Gemtuzumab ozogamicin	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic drug Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .

Sasanlimab PF-06801591	PD-1/PD-L1	Others Cancer
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

Sabatolimab 1 Publications Verification MBG453	Tim3	Inflammation/Immunology Cancer
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

Metelimumab 1 Publications Verification CAT-192; Anti-TGFB1 Recombinant Antibody	TGF-β Receptor	Inflammation/Immunology
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .

Evinacumab REGN1500	ANGPTL Others	Cardiovascular Disease Metabolic Disease
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .

Manfidokimab AK120	Interleukin Related	Inflammation/Immunology
Manfidokimab (AK120) is an anti-interleukin 4 receptor alpha (IL-4Rα) IgG4 monoclonal antibody .

Lipustobart	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .

Tomaralimab OPN-305	Toll-like Receptor (TLR)	Inflammation/Immunology
Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS) .

Nofazinlimab CS1003	PD-1/PD-L1	Cancer
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

Nivolumab Maximum Cited Publications 19 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

Zigakibart BION-1301	TNF Receptor	Inflammation/Immunology Cancer
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .

Crotedumab REGN1193; Anti-GCGR Reference Antibody (crotedumab)	GCGR	Metabolic Disease
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes .

Inclacumab 1 Publications Verification Anti-Human selectin P Recombinant Antibody	P-selectin	Cardiovascular Disease
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a K_d value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC₅₀ value of 1.9 μg/mL and strongly inhibits cell adhesion .

Eblasakimab ASLAN004; CSL-334	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

Ligufalimab AK 117	CD47 Interleukin Related	Cancer
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .

Lerdelimumab CAT-152	TGF-beta/Smad	Neurological Disease
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .

Anumigilimab CSL-324	c-Fms	Inflammation/Immunology
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .

Pucotenlimab HX008	PD-1/PD-L1	Cancer
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .

Tuvonralimab PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105	PD-1/PD-L1 CTLA-4	Cancer
Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab .

Axatilimab SNDX-6352	c-Fms	Inflammation/Immunology Cancer
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .

Odronextamab	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

Cat. No.	Product Name	Target	Research Area

HY-P10722

Efpegerglucagon	Peptides	Inflammation/Immunology
Efpegerglucagon is an Fc fragment of human immunoglobulin G4 (IgG4), formed as a disulfide-bonded dimer. One of the Fc chains is linked via a bifunctional maleimide-polyethylene glycol-aldehyde linker to a glucagon peptide analogue .

Cat. No.	Product Name	Target	Research Area

HY-P99987

*Human IgG4* (S228P) lambda1, Isotype Control**	Inhibitory Antibodies	Inflammation/Immunology
Human IgG4 (S228P) lambda1, Isotype Control, a human-mouse chimeric monoclonal antibody, is an isotype control for human IgG4 (S228P) λ1 antibody.

HY-P99003

*Human IgG4* (S228P) kappa, Isotype Control** 2 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology
Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.

HY-P9902

Pembrolizumab 10+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99026

Lemzoparlimab TJ011133; TJC4	CD47	Cancer
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .

HY-P99517

Voxalatamab JNJ-63898081	CD3	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .

HY-P99021

Galcanezumab LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

HY-P99027

Ieramilimab LAG525; IMP701	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .

HY-P99631

Garadacimab 1 Publications Verification CSL312	Factor Xa	Cardiovascular Disease
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .

HY-P99448

Atinumab 6A3-IgG4; ATI355	Inhibitory Antibodies	Neurological Disease
Atinumab (6A3-IgG4) is an antibody. Teropavimab can be used for the research of spinal cord injury (SCI) .

HY-P99457

Balstilimab AGEN2034	PD-1/PD-L1	Inflammation/Immunology Cancer
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .

HY-P99632

Garetosmab REGN 2477	TGF-β Receptor	Inflammation/Immunology
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .

HY-P99389

Tesnatilimab	Inhibitory Antibodies	Inflammation/Immunology
Tesnatilimab is a human *IgG4* monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD) .

HY-P99028

Ibalizumab TMB-355; TNX-355	HIV	Infection
Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .

HY-P99053

Tralokinumab	Interleukin Related	Inflammation/Immunology
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

HY-P990696

Resugosbart SHR-1222	Inhibitory Antibodies	Inflammation/Immunology
Resugosbart is an anti-SOST human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990737

Eltrekibart	Inhibitory Antibodies	Inflammation/Immunology
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990758

Reflocibart	VEGFR	Inflammation/Immunology
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990773

Venanprubart	Inhibitory Antibodies	Inflammation/Immunology
Venanprubart is an anti-BTLA human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990755

Pamvatamig	EGFR	Inflammation/Immunology
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990691

Vilamakitug XB-2001	PD-1/PD-L1	Inflammation/Immunology
Vilamakitug is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990702

Pradusinstobart LVGN-3616	PD-1/PD-L1	Inflammation/Immunology
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990726

Abiprubart	Inhibitory Antibodies	Inflammation/Immunology
Abiprubart is an anti-CD40 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990743

Gruticibart	Inhibitory Antibodies	Inflammation/Immunology
Gruticibart is an anti-F11 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990750

Negalstobart	LAG-3	Inflammation/Immunology
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99236

Bexmarilimab FP-1305	Inhibitory Antibodies	Inflammation/Immunology Cancer
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer .

HY-P990761

Roconkibart	Interleukin Related	Inflammation/Immunology
Roconkibart is an anti-IL17A human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P99106

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

HY-P99490

Burfiralimab hzVSF-v13	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P990751

Nelmastobart	Inhibitory Antibodies	Inflammation/Immunology
Nelmastobart is an anti-BTN1A1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990777

Vipalanebart	Inhibitory Antibodies	Inflammation/Immunology
Vipalanebart is an anti-ADCYAP1R human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990752

Nezastomig REGN-5678	CD28	Inflammation/Immunology
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990692

Ciduvectamig	Inhibitory Antibodies	Inflammation/Immunology
Ciduvectamig is an anti-CD3E/TMEFF2 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P990683

Satumomab	Inhibitory Antibodies	Inflammation/Immunology
Satumomab is an anti-TAG-72 IgG4-G2a κ monoclonal antibody .

HY-P99495

Cedelizumab RWJ 49004	Inhibitory Antibodies	Inflammation/Immunology
Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties .

HY-P990066

Atisnolerbart	Inhibitory Antibodies	Others
Atisnolerbart is a human IgG4 antibody targeting BETVIA, the major birch pollen allergen Bet v 1-A.

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Others Cancer
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99044

Sabatolimab 1 Publications Verification MBG453	Tim3	Inflammation/Immunology Cancer
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P990065

Bremzalerbart	Inhibitory Antibodies	Others
Bremzalerbart is a human IgG4 antibody targeting BETVIA, the major birch pollen allergen Bet v 1-A .

HY-P99305

Metelimumab 1 Publications Verification CAT-192; Anti-TGFB1 Recombinant Antibody	TGF-β Receptor	Inflammation/Immunology
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .

HY-P99194

Evinacumab REGN1500	ANGPTL Inhibitory Antibodies	Cardiovascular Disease Metabolic Disease
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .

HY-P99724

Manfidokimab AK120	Interleukin Related	Inflammation/Immunology
Manfidokimab (AK120) is an anti-interleukin 4 receptor alpha (IL-4Rα) IgG4 monoclonal antibody .

HY-P990770

Ucenprubart	Inhibitory Antibodies	Inflammation/Immunology
Ucenprubart is an anti-CD200R1 human IgG4κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990072

Lipustobart	PD-1/PD-L1	Cancer
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR)	Inflammation/Immunology
Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS) .

HY-P99758

Nofazinlimab CS1003	PD-1/PD-L1	Cancer
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P9902

Pembrolizumab 10+ Cited Publications MK-3475; Lambrolizumab	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99026

Lemzoparlimab TJ011133; TJC4	Classification of Application Fields Disease Research Fields Cancer	CD47
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .

HY-P99027

Ieramilimab LAG525; IMP701	Classification of Application Fields Disease Research Fields Cancer	LAG-3
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .

HY-P99236

Bexmarilimab FP-1305	Classification of Application Fields Disease Research Fields Cancer	Others
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer .

HY-P99044

Sabatolimab 1 Publications Verification MBG453	Classification of Application Fields Disease Research Fields Cancer	Tim3
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

HY-P99220

Tabalumab LY2127399	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P99758

Nofazinlimab CS1003	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .

HY-P9903

Nivolumab Maximum Cited Publications 19 Publications Verification BMS-936558; ONO-4538; MDX-1106	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99457

Balstilimab AGEN2034	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 .

HY-P99884

Sasanlimab PF-06801591	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .

HY-P99203

Cemiplimab	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P990070

Zigakibart BION-1301	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .

HY-P990061

Polzastobart JTX 8064	Classification of Application Fields Disease Research Fields Cancer	Others
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .

HY-P99938

Pucotenlimab HX008	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .

HY-P99540

Tuvonralimab PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1 CTLA-4
Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab .

HY-P99452

Axatilimab SNDX-6352	Classification of Application Fields Disease Research Fields Cancer	c-Fms
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .

HY-P99055

Urelumab	Classification of Application Fields Disease Research Fields Cancer	Others
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99038

Odronextamab	Classification of Application Fields Disease Research Fields Cancer	CD20 CD3
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99363

Feladilimab Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609	Classification of Application Fields Disease Research Fields Cancer	Others
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer .

HY-P99192

Emibetuzumab LY2875358	Classification of Application Fields Disease Research Fields Cancer	c-Met/HGFR
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	CXCR
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99114

Sugemalimab	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	Classification of Application Fields Disease Research Fields Cancer	MMP
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-P99422

Adebrelimab SHR-1316	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1 Apoptosis
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-P99697

Leronlimab PRO 140	Classification of Application Fields Disease Research Fields Cancer	CCR HIV
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

HY-P99714

Lorigerlimab MGD019	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1 CTLA-4
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and *CTLA-4*, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99971

Gemtuzumab	Classification of Application Fields Disease Research Fields Cancer	ADC Antibody
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-P99913

Eflapegrastim	Classification of Application Fields Disease Research Fields Cancer	c-Fms
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .

HY-P99744

Modakafusp alfa TAK-573	Classification of Application Fields Disease Research Fields Cancer	CD38
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 *IgG4* monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice ^[4].

HY-P99100

Visugromab 1 Publications Verification CTL-002	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .

HY-P99048

Sintilimab IBI308	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Sintilimab (IBI308) is a safe and effectivel humanized *IgG4* monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer ^[4] .

HY-P99333

Volociximab M200; Eos 200-4	Classification of Application Fields Disease Research Fields Cancer	Integrin
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-P9971

Camrelizumab 2 Publications Verification SHR-1210	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-108831

Natalizumab 2 Publications Verification	Classification of Application Fields Disease Research Fields Cancer	Integrin
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99573

Tebotelimab MGD-013	Classification of Application Fields Disease Research Fields Cancer	LAG-3
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P99966

Narlumosbart	Classification of Application Fields Disease Research Fields Cancer	RANKL/RANK
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

HY-P99643

Ginisortamab UCB6114	Classification of Application Fields Disease Research Fields Cancer	Others
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1 monoclonal antibody. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .

HY-P99299

Lexatumumab HGS-ETR 2; ETR2-ST01	Classification of Application Fields Disease Research Fields Cancer	Apoptosis
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-P99668

Iparomlimab	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1 Interleukin Related TNF Receptor
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (K_d=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

Recombinant Proteins Recommended:

IgG4

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P70771

	IgG4 Fc Protein, Human (HEK293) 1 Publications Verification Ig gamma-4 chain C region,IgG4 Fc	Human	HEK293
	The IgG4 Fc is the constant region of the immunoglobulin heavy chain, which forms the backbone of antibodies crucial in humoral immunity. B lymphocytes produce glycoprotein antibodies that initiate clonal expansion upon antigen binding. IgG4 Fc Protein, Human (HEK293) is the recombinant human-derived IgG4 Fc protein, expressed by HEK293 , with tag free. The total length of IgG4 Fc Protein, Human (HEK293) is 228 a.a., with molecular weight of ~32.0 kDa.

HY-P70669

	CD64 Protein, Human (HEK293, His) 1 Publications Verification Ig gamma-4 chain C region,IgG4 Fc	Human	HEK293
	CD64 protein, a high affinity receptor, mediates IgG effector functions, triggering antibody-dependent cellular cytotoxicity (ADCC). It interacts with IGHG1 and forms a signaling complex with FCERG1, contributing to immune responses. CD64 also interacts with FLNA, EPB41L2, LAT, PPL, HCK, and LYN to prevent degradation of FCGR1A and regulate immune function. CD64 Protein, Human (HEK293, His) is the recombinant human-derived CD64 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83582

	*Human IgG4* Antibody (YA3327)** IgG4; Ig gamma 4 chain C region	WB, IHC-P	Human
	Human IgG4 Antibody (YA3327) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3327), targeting Human IgG4, with a predicted molecular weight of 36 kDa (observed band size: 36 kDa). Human IgG4 Antibody (YA3327) can be used for WB, IHC-P experiment in human background.